Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Rodeberg

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Journal of Pediatric Surgery|August 7, 2023
Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer CommitteeLindsay J Talbot, Timothy B Lautz, Jennifer H Aldrink, et al.
Cancer|October 24, 2018
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology GroupSuman Malempati, Brenda J Weigel, Yueh-Yun Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology GroupDavid A Rodeberg, Norbert Garcia-Henriquez, Elizabeth R Lyden, et al.
Cancer Medicine|August 29, 2019
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology GroupEmily Hibbitts, Yueh-Yun Chi, Douglas S Hawkins, et al.
Journal of Pediatric Surgery|May 12, 2021
Update on pediatric testicular germ cell tumorsJennifer H Aldrink, Richard D Glick, Reto M Baertschiger, et al.
Pediatric Blood & Cancer|August 15, 2022
Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)Kirk D Wyatt, Suzi Birz, Douglas S Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803Carola A S Arndt, Julie A Stoner, Douglas S Hawkins, et al.
International Journal of Cancer|May 18, 2010
Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors CommitteeDavid A Rodeberg, James R Anderson, Carola A Arndt, et al.
Journal of Pediatric Surgery|March 11, 2020
Minimally invasive surgery for abdominal and thoracic neuroblastic tumors: A systematic review by the APSA Cancer committeeJuan P Gurria, Marcus M Malek, Todd E Heaton, et al.
Pediatric Blood & Cancer|March 7, 2022
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology GroupJacquelyn N Crane, Wei Xue, Amira Qumseya, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Journal of Pediatric Surgery|August 7, 2023
Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer CommitteeLindsay J Talbot, Timothy B Lautz, Jennifer H Aldrink, et al.
Cancer|October 24, 2018
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology GroupSuman Malempati, Brenda J Weigel, Yueh-Yun Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology GroupDavid A Rodeberg, Norbert Garcia-Henriquez, Elizabeth R Lyden, et al.
Cancer Medicine|August 29, 2019
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology GroupEmily Hibbitts, Yueh-Yun Chi, Douglas S Hawkins, et al.
Journal of Pediatric Surgery|May 12, 2021
Update on pediatric testicular germ cell tumorsJennifer H Aldrink, Richard D Glick, Reto M Baertschiger, et al.
Pediatric Blood & Cancer|August 15, 2022
Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)Kirk D Wyatt, Suzi Birz, Douglas S Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803Carola A S Arndt, Julie A Stoner, Douglas S Hawkins, et al.
International Journal of Cancer|May 18, 2010
Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors CommitteeDavid A Rodeberg, James R Anderson, Carola A Arndt, et al.
Journal of Pediatric Surgery|March 11, 2020
Minimally invasive surgery for abdominal and thoracic neuroblastic tumors: A systematic review by the APSA Cancer committeeJuan P Gurria, Marcus M Malek, Todd E Heaton, et al.
Pediatric Blood & Cancer|March 7, 2022
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology GroupJacquelyn N Crane, Wei Xue, Amira Qumseya, et al.
Pageof 7